New perspectives on endocrine therapy suitability for hormone receptor-positive metastatic breast cancer in clinical practice
Experts propose refined decision-making framework for sequencing breast cancer hormonal therapies based on individual resistance patterns.
An international expert panel funded by AstraZeneca proposes a new clinical framework ('ET suitability') for individualized treatment decision-making in HR+ metastatic breast cancer, acknowledging gaps in existing guideline definitions of ET resistance and the need for biomarker-guided therapy sequencing. The framework concept is useful but the underlying evidence is largely existing data.
What the study was
- Study design
- Expert review/opinion
- Population
- Patients with HR+/HER2- metastatic breast cancer
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Breast (Edinburgh, Scotland)
Why it surfaced
Expert opinion framework article from high-profile international breast cancer experts. Moderate clinical utility as a framework summary but no new clinical data generated. Multiple authors' COI: article publishing charges paid by AstraZeneca. Score reflects opinion/review classification with industry funding disclosure.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.